Predictors of b/tsDMARDs discontinuation and treatment response in psoriatic arthritis: results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA)

OBJECTIVES: Despite advances in biologic and targeted synthetic DMARDs (b/tsDMARDs), many patients with psoriatic arthritis (PsA) experience suboptimal responses and discontinue therapy. We aimed, in a real-world registry, to identify predictors of b/tsDMARD discontinuation and treatment response. METHODS: Patients commencing b/tsDMARD therapy were identified from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‑PsA). Clinical and patient‑reported measures were collected at treatment start. Cox regression identified predictors of drug discontinuation using multiple imputation with predictive mean matching to handle missing data, and logistic regression identified predictors of achieving 12-month Minimal Disease Activity (MDA), ACR50 and PsARC response. RESULTS: Eight-hundred and fifteen participants were included; 40% male, median age 51 years, with high disease activity (median DAPSA 33.5; PASDAS 5.9). At censoring (01‑Aug‑2025), 65% remained on their index therapy (median exposure 31 months) with discontinuation primarily due to inefficacy (55%) or intolerance (26%). Patients commencing PDE4 inhibition experienced more than a doubling in the risk of discontinuation, compared to those starting TNF inhibitors (Hazard Ratio: 2.25; 95%CI: 1.45-3.50), while no major differences were observed with other modes of action. At 12-months, 24% achieved MDA, 24% ACR50, and 49% PsARC. Based on imputed outcomes, men, younger individuals, and those who were employed were consistently more likely to achieve treatment response, while poorer baseline clinical or patient‑reported measures predicted non‑response. CONCLUSIONS: Treatment persistence and response in PsA remain a problem and are strongly influenced by demographic factors and baseline disease severity. A better understanding of predictors of non-response may aid future risk stratification.

Authors

Institutions

Publication Details

Journal
Lara D. Veeken
Published
2026-10-27
DOI
https://doi.org/10.1093/rheumatology/keag598
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predictors of b/tsDMARDs discontinuation and treatment response in psoriatic arthritis: results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA)

Ovidiu Rotariu, Philip Helliwell, Gary John Macfarlane, Stefan Siebert et al.
2 links
Lara D. Veeken
Spondyloarthritis Studies and Treatments
article

Predictors of b/tsDMARDs discontinuation and treatment response in psoriatic arthritis: results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA)

Ovidiu Rotariu, Philip Helliwell, Gary John Macfarlane, Stefan Siebert, Gareth Tudor Jones, Stephanie Lembke
article en

Abstract

OBJECTIVES: Despite advances in biologic and targeted synthetic DMARDs (b/tsDMARDs), many patients with psoriatic arthritis (PsA) experience suboptimal responses and discontinue therapy. We aimed, in a real-world registry, to identify predictors of b/tsDMARD discontinuation and treatment response. METHODS: Patients commencing b/tsDMARD therapy were identified from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‑PsA). Clinical and patient‑reported measures were collected at treatment start. Cox regression identified predictors of drug discontinuation using multiple imputation with predictive mean matching to handle missing data, and logistic regression identified predictors of achieving 12-month Minimal Disease Activity (MDA), ACR50 and PsARC response. RESULTS: Eight-hundred and fifteen participants were included; 40% male, median age 51 years, with high disease activity (median DAPSA 33.5; PASDAS 5.9). At censoring (01‑Aug‑2025), 65% remained on their index therapy (median exposure 31 months) with discontinuation primarily due to inefficacy (55%) or intolerance (26%). Patients commencing PDE4 inhibition experienced more than a doubling in the risk of discontinuation, compared to those starting TNF inhibitors (Hazard Ratio: 2.25; 95%CI: 1.45-3.50), while no major differences were observed with other modes of action. At 12-months, 24% achieved MDA, 24% ACR50, and 49% PsARC. Based on imputed outcomes, men, younger individuals, and those who were employed were consistently more likely to achieve treatment response, while poorer baseline clinical or patient‑reported measures predicted non‑response. CONCLUSIONS: Treatment persistence and response in PsA remain a problem and are strongly influenced by demographic factors and baseline disease severity. A better understanding of predictors of non-response may aid future risk stratification.

Lara D. Veeken
University of Leeds (GB), University of Aberdeen (GB), German Rheumatism Research Centre (DE), University of Glasgow (GB)
Amgen, British Society for Rheumatology
Good health and well-being
Openalex Percentile: Top 11%
Spondyloarthritis Studies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon